Welcome to our dedicated page for Cybin news (Ticker: $CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cybin's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cybin's position in the market.
Rhea-AI Summary
Cybin Inc. receives Breakthrough Therapy Designation from the FDA for CYB003, a psychedelic-based therapy for Major Depressive Disorder. Positive Phase 2 trial results show significant improvement in depression symptoms with 75% remission after two doses. The company plans to progress to a Phase 3 study in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
-
Rhea-AI Summary
Cybin Inc. announces a program update on CYB003, a Phase 2 trial for Major Depressive Disorder, including 4-month durability data. Company executives will host a conference call to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
-
Rhea-AI Summary
Cybin Inc. announces CEO's presentation at TD Cowen 44th Annual Health Care Conference in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
Rhea-AI Summary
Cybin Inc. reports positive Phase 2 results for CYB003 in Major Depressive Disorder, with a 79% remission rate. Positive Phase 1 results for CYB004 and SPL028. FDA clearance for CYB004 Phase 2a study in Generalized Anxiety Disorder. Strengthened IP portfolio with over 50 patents. Financial data shows cash availability of C$39.0 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
-
Rhea-AI Summary
Cybin Inc. announces the granting of two patents by the Japan Patent Office for injectable formulations and synthesis methods for the preparation of DMT and dDMT, further strengthening its intellectual property portfolio. The patents are expected to provide exclusivity until at least 2040 and 2041, respectively. This adds to Cybin's existing U.S. and European patent portfolio and provides protection for its proprietary DMT program in another important region. The company also received clearance from the U.S. FDA for its investigational new drug application for CYB004, its proprietary dDMT molecule in development for the treatment of Generalized Anxiety Disorder (GAD). Positive safety, pharmacokinetic, and pharmacodynamic data were announced from Phase 1 studies of CYB004 and SPL028 in healthy volunteers. Cybin plans to initiate a Phase 2a study of CYB004 in Q1 2024, assessing its preliminary clinical efficacy, safety, tolerability, PK, and PD in participants with GAD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
-
News
Rhea-AI Summary
Cybin Inc. announced positive Phase 1 results for its proprietary deuterated DMT molecule, CYB004, for the treatment of Generalized Anxiety Disorder (GAD). The FDA has cleared the company's investigational new drug application, allowing them to proceed with a Phase 2a study in Q1 2024. The study will assess the clinical efficacy, safety, and tolerability of CYB004 in participants with GAD. The company aims to develop improved treatment options for anxiety disorders, addressing the limitations of current options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
Rhea-AI Summary
Cybin Inc. (CYBN) Announces Positive Phase 1 Results for CYB004 and SPL028 in Generalized Anxiety Disorder Treatment Development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
-
Rhea-AI Summary
Cybin Inc. (CYBN) announces positive Phase 2 topline data for CYB003 in Major Depressive Disorder, with 79% of patients in remission from depression after two doses. The company also outlines near-term milestones and upcoming trials for its clinical-stage deuterated psilocybin and dDMT programs in development for the treatment of multiple mental health conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
-
Rhea-AI Summary
InvestorsObserver Critical PriceWatch Alerts: MSAI, DUNE, M, CYBN, and SXTP
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
Rhea-AI Summary
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) announced the granting of U.S. patent 11,834,410 supporting its CYB003 deuterated psilocybin analog program, providing protection until at least 2041. The patent includes composition of matter claims to pharmaceutical compositions for major depressive disorder, treatment-resistant depression, and alcohol use disorder. Positive Phase 2 topline data showed 79% of MDD patients in remission after two 12mg doses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
Cybin Inc.
NYSE:CYBN
CYBN Rankings
CYBN Stock Data
280.34M
322.71M
6.66%
23.08%
3.03%
Medicinal and Botanical Manufacturing
Manufacturing
United States of America
Toronto